Menu

  1. Home
  2.  / 
  3. Free Paper, Orbit & Oculoplasty - I
  4.  / 
  5. FP0919 : TRAMB as an “eye saver” in post COVID-19 ROCM

Share this post

DR.ABHISHEK SHEEMAR

Prof.DR. KAVITA RAJAN BHATNAGAR, DR. JYOTI SHAKRAWAL, DR. SEEMA MEENA, DR.ABHISHEK SHEEMAR

Abstract

Aim:To report the outcomes of transcutaneous retro-bulbar amphotericin-B(TRAMB) for ROCM post COVID-19. Methods:44 eyes with ROCM staging ≥3B received TRAMB and 28 eyes with stage 3A were kept on follow-up. Potential eyes for exenteration were excluded. Results:TRAMB group had significantly uncontrolled DM &amp; steroid treatment received during COVID-19 than other group. Eyes which showed improvement/stable on radiology &amp; improvement in vision were significantly more in TRAMB group(p<0.001). 4 eyes in TRAMB group &amp; 9 in other group showed progression of the disease, which were augmented with further TRAMB(p<0.001). Sinus redebridement were significantly less in TRAMB(p<0.001). No patient required exenteration in TRAMB group. SCH occurred in 6 &amp; temporary vision loss in 4 eyes after TRAMB which resolved spontaneously. Conclusion: TRAMB is associated with a significant reduction or stabilization of orbital involvement. TRAMB significantly aid in avoidance of exenteration and saving sight.

Full Text  

 

Leave a Comment